ORXOYライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (24 4月 2024 @ 23:02):

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom...

Stats
本日の出来高	655.00
平均出来高	69.00
時価総額	48.23M
EPS	$-0.967 ( 2023-09-30 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.12
ATR14	$0 (0.00%)

Orexo AB (publ) 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Orexo AB (publ) 財務諸表

Annual	2023
収益:	$638.80M
総利益:	$472.80M (74.01 %)
EPS:	$-3.73

FY	2023
収益:	$638.80M
総利益:	$472.80M (74.01 %)
EPS:	$-3.73

FY	2022
収益:	$624.30M
総利益:	$521.70M (83.57 %)
EPS:	$-5.17

FY	2021
収益:	$565.00M
総利益:	$486.10M (86.04 %)
EPS:	$-2.13

Financial Reports:

No articles found.

Orexo AB (publ)

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.